PURPOSE: Acute onset supraventricular arrhythmias can contribute to haemodynamic compromise in septic shock. Both amiodarone and propafenone are available interventions, but their clinical effects have not yet been directly compared. METHODS: In this two-centre, prospective controlled parallel group double blind trial we recruited 209 septic shock patients with new-onset arrhythmia and a left ventricular ejection fraction above 35%. The patients were randomised in a 1:1 ratio to receive either intravenous propafenone (70 mg bolus followed by 400-840 mg/24 h) or amiodarone (300 mg bolus followed by 600-1800 mg/24 h). The primary outcomes were the proportion of patients who had sinus rhythm 24 h after the start of the infusion, time to restoration of the first sinus rhythm and the proportion of patients with arrhythmia recurrence. RESULTS: Out of 209 randomized patients, 200 (96%) received the study drug. After 24 h, 77 (72.8%) and 71 (67.3%) were in sinus rhythm (p = 0.4), restored after a median of 3.7 h (95% CI 2.3-6.8) and 7.3 h (95% CI 5-11), p = 0.02, with propafenone and amiodarone, respectively. The arrhythmia recurred in 54 (52%) patients treated with propafenone and in 80 (76%) with amiodarone, p < 0.001. Patients with a dilated left atrium had better rhythm control with amiodarone (6.4 h (95% CI 3.5; 14.1) until cardioversion vs 18 h (95% CI 2.8; 24.7) in propafenone, p = 0.05). CONCLUSION: Propafenone does not provide better rhythm control at 24 h yet offers faster cardioversion with fewer arrhythmia recurrences than with amiodarone, especially in patients with a non-dilated left atrium. No differences between propafenone and amiodarone on the prespecified short- and long-term outcomes were observed.

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Anesthesiology and Intensive Care 1st Faculty of Medicine Charles University and General University Hospital Prague U Nemocnice 2 128 00 Prague 2 Czech Republic

Department of Anesthesiology and Intensive Care 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Arrigo M, Bettex D, Rudiger A (2014) Management of atrial fibrillation in critically ill patients. Crit Care Res Prac 2014:840615

Klein Klouwenberg PM FJ, Kuipers S, Ong DS, Peelen LM, van Vught LA, Schultz MJ, van der Poll T, Bonten MJ, Cremer OL, MARS Consortium (2016) Incidence, predictors and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis: a cohort study. Am J Respir Crit Care Med

Kuipers S, Klein Klouwenberg P, Cremer OL (2014) Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. Crit Care 18:688 PubMed DOI PMC

Arrigo M, Jaeger N, Seifert B, Spahn DR, Bettex D, Rudiger A (2015) Disappointing success of electrical cardioversion for new-onset atrial fibrillation in cardiosurgical ICU patients. Crit Care Med 43:2354–2359 PubMed DOI

Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J (2017) Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol. J Crit Care 41:16–23 PubMed DOI

O’Bryan LJ, Redfern OC, Bedford J, Petrinic T, Young JD, Watkinson PJ (2020) Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review. BMJ Open 10:e034774 PubMed DOI PMC

Allen LaPointe NM, Dai D, Thomas L, Piccini JP, Peterson ED, Al-Khatib SM (2015) Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. Am J Cardiol 115:316–322 PubMed DOI

Balik M, Matousek V, Maly M, Brozek T (2017) Management of arrhythmia in sepsis and septic shock. Anaesthesiol Intensive Ther 49:419–429 PubMed DOI

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373–498 PubMed DOI

Wetterslev M, Møller MH, Granholm A, Hassager C, Haase N, Aslam TN, Shen J, Young PJ, Aneman A, Hästbacka J, Siegemund M, Cronhjort M, Lindqvist E, Myatra SN, Kalvit K, Arabi YM, Szczeklik W, Sigurdsson MI, Balik M, Keus F, Perner A (2022) Management of acute atrial fibrillation in the intensive care unit: an international survey. Acta Anaesthesiol Scand 66:375–385 PubMed DOI

Gwag HB, Chun KJ, Hwang JK, Park SJ, Kim JS, Park KM, On YK (2018) Which antiarrhythmic drug to choose after electrical cardioversion: a study on non-valvular atrial fibrillation patients. PLoS ONE 13:e0197352 PubMed DOI PMC

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962 PubMed DOI

Echt DSLP, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. NEJM 324:781–788 PubMed DOI

Chevalier PD-DA, Burri H, Cucherat M, Kirkorian G, Touboul P (2003) Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41:255–262 PubMed DOI

Courand PYSF, Ranc S, Mullier A, Kirkorian G, Bonnefoy E (2013) Arrhythmogenic effect of flecainide toxicity. Cardiol J 20:203–205 PubMed DOI

Varon J, Marik PE (2008) Irwin and Rippe’s intensive care medicine. In: Rippe JM (ed) Irwin RS. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, pp 1855–1869

Ganetsky M (2008) Antiarythmic agents. In: Irwin RS (ed) Intensive care medicine. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia, pp 1486–1498

Stoschitzky K, Stoschitzky G, Lercher P, Brussee H, Lamprecht G, Lindner W (2016) Propafenone shows class Ic and class II antiarrhythmic effects. Europace 18:568–571 PubMed DOI

Lafuente-Lafuente C, Valembois L, Bergmann JF, Belmin J (2015) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev Cd005049

Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C (2019) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 9:Cd005049 PubMed

Balik M, Waldauf P, Maly M, Matousek V, Brozek T, Rulisek J, Porizka M, Sachl R, Otahal M, Brestovansky P, Svobodova E, Flaksa M, Stach Z, Pazout J, Duska F, Smid O, Stritesky M (2019) Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study. BMJ Open 9:e031678 PubMed DOI PMC

Singer MDC, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810 PubMed DOI PMC

Team RC (2022) A language and environment for statistical computing

Team P (2022) RStudio: integrated development environment for R. Posit Software

Bonora A, Turcato G, Franchi E, Taioli G, Dilda A, Zerman G, Maccagnani A, Pistorelli C, Olivieri O (2017) Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern Emerg Med 12:853–859 PubMed DOI

Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS (1994) Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 23:1535–1540 PubMed DOI

Grundvold I, Tveit A, Smith P, Seljeflot I, Abdelnoor M, Arnesen H (2008) The predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled study. Cardiology 111:30–35 PubMed DOI

Otto C (2012) The role of echocardiography in atrial fibrillation and flutter. In: Otto C (ed) The practice of clinical echocardiography. Elsevier Health Sciences, Philadelphia, pp 821–827

Balik M, Rulisek J, Leden P, Zakharchenko M, Otahal M, Bartakova H, Korinek J (2012) Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wien Klin Wochenschr 124:552–556 PubMed DOI

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D’Egidio A, D’Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691 PubMed DOI

Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833 PubMed DOI

Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, Ailawadi G, Kirkwood KA, Perrault LP, Parides MK, Smith RL 2nd, Kern JA, Dussault G, Hackmann AE, Jeffries NO, Miller MA, Taddei-Peters WC, Rose EA, Weisel RD, Williams DL, Mangusan RF, Argenziano M, Moquete EG, O’Sullivan KL, Pellerin M, Shah KJ, Gammie JS, Mayer ML, Voisine P, Gelijns AC, O’Gara PT, Mack MJ (2016) Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 374:1911–1921 PubMed DOI PMC

Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840 PubMed DOI

McLean AS, Taccone FS, Vieillard-Baron A (2016) Beta-blockers in septic shock to optimize hemodynamics? No. Intensive Care Med 42:1610–1612 PubMed DOI

McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, Lamontagne F, Healey JS, Whitlock RP, Belley-Côté EP (2018) Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA 319:1889–1900 PubMed DOI PMC

Balik M (2018) New-onset atrial fibrillation in critically ill patients—implications for rhythm rather than rate control therapy? Int J Cardiol 266:147–148 PubMed DOI

Sterling SA, Puskarich MA, Glass AF, Guirgis F, Jones AE (2017) The impact of the sepsis-3 septic shock definition on previously defined septic shock patients. Crit Care Med 45:1436–1442 PubMed DOI PMC

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256 PubMed DOI

Beta-blockers as antiarrhythmics in septic shock: a light at the end of the tunnel?

Personalizing beta-blockade in septic shock: finding the right rhythm and rate for the right patient

Research priorities for the study of atrial fibrillation during acute and critical illness: recommendations from the Symposium on Atrial Fibrillation in Acute and Critical Care